Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Adam FeuersteinVerified account ?@adamfeuerstein 11m11 minutes ago
Bo is the source of the $ACAD takeout rumor.
https://twitter.com/adamfeuerstein
ACAD
2 X's regular volume today. Last trade 318739 shares @ $1.90.
A Baker Bro squeeze.
IDRA
Keep posting!! It's just been to $1.84. Hopefully sets its pattern of trading sideways past 10:00 am or continues to climb back over $2.00.
IDRA
Can see this clearly on Google finance which allows you to overlay the charts (gotta add IBB at compare):
https://www.google.com/finance?q=idra&ei=LhUGWIDBFIaQmAHhyZ54
Guess IDRA moves up when the sector moves.
IDRA
Wasn't aware of any regulations concerning those or similar filings. Why would the company not PR the closing?
I know it is down the last few days because of the overall market, but assuming that an announced closing of the offering would provide some upward momentum. Of course Pillar and BB are aware of anything as insiders.
IDRA
I don't believe it has closed. I'm thinking and hoping that is the issue with this poor performance. We are 12 days past the initial announcement which seems excessive don't you think?
IDRA
Pillar Pharmaceuticals I, LP Maintains 19.9% Stake in Idera Pharmaceuticals Inc. (IDRA)
October 17th, 2016 - 0 comments - Filed Under - by Trevor Kearing
Idera Pharmaceuticals logoPillar Pharmaceuticals I, LP revealed that they own 19.9% of Idera Pharmaceuticals Inc. (NASDAQ:IDRA) in a Schedule 13D/A disclosure that was filed with the Securities and Exchange Commission (SEC) on Monday, October 17th. The investor owns 29,253,115 shares of the stock worth about $52,070,545. The reporting parties listed on the disclosure included Pillar Pharmaceuticals I, LP, Pillar Pharmaceuticals II, LP, Pillar Pharmaceuticals III, LP, Pillar Pharmaceuticals IV, LP, Pillar Pharmaceuticals V, LP, Pillar Invest Corporation and Youssef El Zein. The filing is available through EDGAR at this link.
Several other hedge funds and other institutional investors have also modified their holdings of the company. JPMorgan Chase & Co. raised its stake in shares of Idera Pharmaceuticals by 5.9% in the first quarter. JPMorgan Chase & Co. now owns 3,349,700 shares of the company’s stock worth $6,632,000 after buying an additional 187,625 shares during the period. State Street Corp raised its position in shares of Idera Pharmaceuticals by 10.7% in the second quarter. State Street Corp now owns 1,332,201 shares of the company’s stock worth $2,041,000 after buying an additional 129,033 shares during the period. BlackRock Fund Advisors raised its position in shares of Idera Pharmaceuticals by 4.3% in the second quarter. BlackRock Fund Advisors now owns 2,332,615 shares of the company’s stock worth $3,569,000 after buying an additional 97,125 shares during the period. BlackRock Investment Management LLC raised its position in shares of Idera Pharmaceuticals by 7.3% in the second quarter. BlackRock Investment Management LLC now owns 334,389 shares of the company’s stock worth $512,000 after buying an additional 22,791 shares during the period. Finally, Creative Planning raised its position in shares of Idera Pharmaceuticals by 11.8% in the second quarter. Creative Planning now owns 121,300 shares of the company’s stock worth $186,000 after buying an additional 12,800 shares during the period. 23.64% of the stock is owned by institutional investors and hedge funds.
Institutional Ownership by Quarter for Idera Pharmaceuticals (NASDAQ:IDRA)
Idera Pharmaceuticals Inc. (NASDAQ:IDRA) opened at 1.78 on Monday. The firm’s market cap is $216.05 million. The company’s 50 day moving average is $2.19 and its 200 day moving average is $1.81. Idera Pharmaceuticals Inc. has a 12-month low of $1.19 and a 12-month high of $4.42.
Idera Pharmaceuticals (NASDAQ:IDRA) last released its earnings results on Tuesday, August 2nd. The company reported ($0.11) EPS for the quarter, hitting analysts’ consensus estimates of ($0.11). Idera Pharmaceuticals had a negative net margin of 6,169.32% and a negative return on equity of 64.09%. On average, equities analysts anticipate that Idera Pharmaceuticals Inc. will post ($0.45) earnings per share for the current year.
A number of equities analysts have weighed in on IDRA shares. Wedbush reiterated an “outperform” rating and issued a $6.00 price target on shares of Idera Pharmaceuticals in a report on Tuesday, August 2nd. Zacks Investment Research lowered shares of Idera Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, August 4th. Finally, S&P Equity Research lifted their price target on shares of Idera Pharmaceuticals from $1.86 to $2.10 in a report on Friday, October 7th.
In other Idera Pharmaceuticals news, Director Julian Baker bought 3,250,000 shares of the company’s stock in a transaction that occurred on Friday, October 7th. The shares were acquired at an average cost of $2.00 per share, for a total transaction of $6,500,000.00. The purchase was disclosed in a legal filing with the SEC, which is available through this link. 29.50% of the stock is currently owned by corporate insiders.
Idera Pharmaceuticals Company Profile
Idera Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics for oncology and rare diseases. The Company utilizes two drug discovery technology platforms to design and develop drug candidates, which include Toll-like receptor (TLR) targeting technology and third-generation antisense (3GA) technology.
__________________________________________________
http://www.dailypolitical.com/2016/10/17/pillar-pharmaceuticals-i-lp-maintains-19-9-stake-in-idera-pharmaceuticals-inc-idra.html
IDRA
2 Small Biotechs To Buy In This Week's Pullback
Oct. 13, 2016 9:11 AM ET|3 comments | About: ACADIA Pharmaceuticals Inc. (ACAD),
Bret Jensen Bret JensenPremium Research »Follow(28,165 followers)
Specializing in biotech stocks, Small Caps, managing optimized portfolios
The biotech sector has been hit hard in the last two trading sessions. The main trigger for this huge shift of sentiment is politics.
The main biotech indices have lost approximately 6.5% of their value in what has been a brutal and indiscriminate decline.
Attempting to make lemonade from lemons, here are two smaller names I would be opportunistically accumulating if one does not already have a full position in them.
"I predict future happiness for Americans, if they can prevent the government from wasting the labors of the people under the pretense of taking care of them." - Thomas Jefferson
The biotech sector has been hit hard in the last two trading sessions. The main biotech indices have lost approximately 6.5% of their value since Tuesday in what has been a brutal and indiscriminate decline. The main trigger for this huge shift of sentiment is politics. Thanks to the recent implosion of the Republicans nominee's presidential campaign fears have grown that the Democrats could engineered a "clean sweep" this November and control all three branches of government. This could result in more regulation as well as other negative legislative actions on the Pharma & Biotech industries.
The Senate could well "flip". However, given how gerrymandered the House districts have become, the high negative ratings of both candidates and the fact two thirds of the nation thinks the country is heading in the wrong direction; a "clean sweep" is still only a 25% or 33% possibility in my view.
I have gotten a lot of questions on what smaller biotech stocks I would add to here after this week's steep decline. Here is a quick synopsis of two "Tier 3" stocks I have covered before I would start to accumulate Thursday if you do not already have a full position. Tier 3 biotech stocks, for those that are not regular readers of my columns; are companies that have recently approved and potentially lucrative new products but have not achieved profitability as of yet.
(info deleted)
Name: Acadia Pharmaceuticals (NASDAQ:ACAD)
Market Cap: $3.05 billion
Stock Price: $25.78 a share
52-week high: $43.30 a share
Median Analyst Price Target: $45.50 a share
Cash On Hand: ~$600 million
Primary Drug: Nuplazid. This compound received recent FDA approval in the second quarter as the first drug to be green lighted for the treatment of psychosis often associated with Parkinson's Disease. This disease affects approximately one million individuals in the United States with around 60,000 new cases annually. Psychosis occurs in 40% of this population. The compound is also in mid/late stage trials to treat the psychosis found in patients with Alzheimers and Schizophrenia. My own view is success for those indications is less than 50/50 but I could easily see physicians using Nuplazid "off label" if the drug shows some effect in those areas. Parkinson's alone should eventually garner $1 billion in annual sales.
Other Factors: Acadia is one of the few mid-caps in the biotech sector which is dominated by "whales" and "minnows". It is often speculated as a buyout target which I think will eventually happen but not until the first half of 2017. Biogen (NASDAQ:BIIB) is the most logical suitor. This company announced earlier this year it would be spinning off its hemophilia business that should be worth between $5 billion and $7 billion. The company has also stated it is interested in expanding its footprint in the neurology space. A hookup with Acadia seems like a match made in heaven.
These are two actionable ideas for biotech investors that want to take advantage of lower entry points created by the substantial pullback in the sector over the past couple of trading sessions.
Note: To get these types of articles on attractive biotech and pharma stocks as soon as they are published, just click on my profile and hit the big orange "follow" button and choose the real-time alerts option.
Thank You & Happy Hunting
Bret Jensen
Founder, Biotech Forum
Disclosure: I am/we are long ACAD,
I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
_______________________________________________________
http://seekingalpha.com/article/4011889-2-small-biotechs-buy-weeks-pullback?app=1&auth_param=udil:1bvv204:7bd0a142951bc9b5d4c0bb67be22eb78&uprof=46
ACAD
Link:
http://www.nasdaq.com/symbol/aezs/sec-filings
The Nasdaq site has a lot of info regarding AEZS.
AEZS
Aeterna Zentaris & Specialised Therapeutics Asia Sign Exclusive License Agreement for the Potential Marketing of Zoptrex™ i...
Date : 10/12/2016 @ 8:00AM
Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the “Company”) and Specialised Therapeutics Asia (“STA”) today announced the signing of an exclusive license agreement for the Company’s lead investigational anti-cancer compound, Zoptrex™ (zoptarelin doxorubicin), for the territories of Australia and New Zealand (the “Territory”). Zoptrex™, a novel synthetic peptide carrier linked to doxorubicin, is currently undergoing a fully-enrolled Phase 3 clinical trial to evaluate the compound in endometrial cancer. The Company expects to complete the Phase 3 clinical trial in 2016 and, if the results of the trial warrant doing so, to submit a new drug application for Zoptrex™ to the United States Food and Drug Administration (FDA) in the first half of 2017. Zoptrex™ is the Company’s proposed tradename for zoptarelin doxorubicin. The proposed tradename is subject to approval by the FDA.
Under the terms of the License Agreement, Aeterna Zentaris will be entitled to receive a non-refundable upfront payment in consideration for the license to STA of the Company’s intellectual property related to Zoptrex™ and the grant to STA of the right to commercialize Zoptrex™ in the Territory. STA has also agreed to make additional payments to the Company upon achieving certain pre-established regulatory and commercial milestones, as well as double-digit royalties on future net sales of Zoptrex™ in the Territory. STA will be responsible for the development, registration, reimbursement and commercialization of the product in the Territory. The Company and STA have also entered into a supply agreement, pursuant to which the Company will supply Zoptrex™ to STA for the duration of the license agreement.
David Dodd, President and CEO of the Company, stated, “I am very pleased that we have now concluded four agreements for the commercial rights to Zoptrex™, if approved, outside the United States. We believe that the interest in Zoptrex expressed by our licensees supports our view that Zoptrex™, if it is approved by the FDA for its initial indication, could be an important treatment option for women with the most severe form of endometrial cancer. We are particularly pleased to have a company of the caliber of STA as a licensee. STA enjoys the highest reputation in its markets and, with its existing portfolio of oncology products, it has the capability to position Zoptrex™ very well in the market.”
STA Chief Executive Officer Mr. Carlo Montagner said Zoptrex™ had demonstrated great potential and was poised to add further value to the company’s expanding oncology portfolio. “All results to date suggest Zoptrex™ is a potent new compound and we look forward to collaborating closely with Aeterna Zentaris to maximise its full potential in our key markets,” he said.
About Zoptrex™
Zoptrex™ (zoptarelin doxorubicin) is a complex molecule that combines a synthetic peptide carrier with doxorubicin, a well-known chemotherapy agent. The synthetic peptide carrier is (D)-Lys6-LHRH, a modified natural hormone believed to have a strong affinity for the LHRH receptor. The design of the compound allows for the specific binding and selective uptake of the cytotoxic conjugate by LHRH receptor-positive tumors. Potential benefits of this targeted approach include enhanced efficacy and a more favorable safety profile with lower incidence and severity of side effects as compared to doxorubicin.
About Specialised Therapeutics Asia
Specialised Therapeutics Asia Pte Ltd (“STA”) is an international biopharmaceutical company established to provide pioneering healthcare solutions to patients throughout South East Asia, as well as in Australia and New Zealand. The company is a close affiliate of Specialised Therapeutics Australia, which also collaborates with leading global pharmaceutical and diagnostic companies to bring novel, innovative and life changing healthcare solutions to patients affected by a range of diseases. STA is committed to making new and novel therapies available to patients around the world, with a broad therapeutic portfolio spanning oncology, hematology, urology and ophthalmology. Additional information can be found at www.specialisedtherapeutics.com.au.
About Aeterna Zentaris Inc.
Aeterna Zentaris is a specialty biopharmaceutical company engaged in developing and commercializing novel treatments in oncology, endocrinology and women’s health. We are engaged in drug development activities and in the promotion of products for others. We are now conducting Phase 3 studies of two internally developed compounds. The focus of our business development efforts is the acquisition or license of products that are relevant to our therapeutic areas of focus. We also intend to license out certain commercial rights of internally developed products to licensees in territories where such out-licensing would enable us to ensure development, registration and launch of our product candidates. Our goal is to become a growth-oriented specialty biopharmaceutical company by pursuing successful development and commercialization of our product portfolio, achieving successful commercial presence and growth, while consistently delivering value to our shareholders, employees and the medical providers and patients who will benefit from our products. For more information, visit www.aezsinc.com.
Forward-Looking Statements
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the US Securities Litigation Reform Act of 1995. Forward-looking statements may include, but are not limited to statements preceded by, followed by, or that include the words “expects,” “believes,” “intends,” “anticipates,” and similar terms that relate to future events, performance, or our results. Forward-looking statements involve known and unknown risks and uncertainties that could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects and clinical trials, the successful and timely completion of clinical studies, the risk that safety and efficacy data from any of our Phase 3 trials may not coincide with the data analyses from previously reported Phase 1 and/or Phase 2 clinical trials, the rejection or non-acceptance of any new drug application by one or more regulatory authorities and, more generally, uncertainties related to the regulatory process, the ability of the Company to efficiently commercialize one or more of its products or product candidates, the degree of market acceptance once our products are approved for commercialization, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, the ability to protect our intellectual property, the potential of liability arising from shareholder lawsuits and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and US securities commissions for additional information on risks and uncertainties relating to forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements. The Company does not undertake to update these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, except if required to do so.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161012005199/en/
Aeterna Zentaris Inc.
Philip A. Theodore, Senior Vice President
IR@aezsinc.com
843-900-3223
or
Specialised Therapeutics Asia
Emma Power, Communications Manager
epower@stabiopharma.com
+61 419 149 525
_______________________________________________
AEZS
Good news, they now hold more:
http://ih.advfn.com/p.php?pid=nmona&article=72643483&symbol=IDRA
I see their buys were at $2.00.
Nice pre-market response so far. Now need confirmation of the closing of the offering.
IDRA
ACADIA Pharmaceuticals Receives California Life Sciences Association’s 2016 Pantheon DiNA Award for Outstanding Therapeutic Product for NUPLAZID™
By Business Wire, October 11, 2016, 09:00:00 AM EDT
SAN DIEGO--(BUSINESS WIRE)--
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system (CNS) disorders, has been awarded the California Life Sciences Association's 2016 Pantheon DiNA Award for Outstanding Therapeutic Product for NUPLAZID™ (pimavanserin), the first and only drug approved by the U.S. Food and Drug Administration for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.
The California Life Sciences Association's (CLSA) DiNA Pantheon Awards recognize achievements and honor excellence in the life sciences sector in California. The Outstanding Therapeutic Product award is given to the most promising or significant new life sciences product approved in the 12 months preceding selection. The selection is made by a panel of life sciences industry leaders, journalists and CLSA board members. This year's winners will be honored at the 2016 Pantheon Awards ceremony on December 2 at the Westin St. Francis in San Francisco.
"We are honored to be recognized for our team's hard work and commitment to discovering, developing and commercializing NUPLAZID," said Steve Davis
, ACADIA's President and Chief Executive Officer. "NUPLAZID represents the culmination of many years of work across our entire organization, and we are gratified by the opportunity to improve the lives of people with Parkinson's disease psychosis."
"We are pleased to honor this first-in-class, first-in-disease medication with this year's Pantheon DiNA Award for Outstanding Therapeutic Product," said Sara Radcliffe
, President and Chief Executive Officer of California Life Sciences Association. "NUPLAZID truly represents the type of innovation and excellence for which the California life sciences sector is known."
About NUPLAZID™ (pimavanserin)
NUPLAZID is the first FDA-approved treatment for hallucinations and delusions associated with Parkinson's disease psychosis. NUPLAZID is a non-dopaminergic, selective serotonin inverse agonist preferentially targeting 5-HT2A receptors that are thought to play an important role in Parkinson's disease psychosis. NUPLAZID is an oral medicine taken once a day with a recommended dose of 34 mg (two 17-mg tablets). ACADIA discovered this new chemical entity and holds worldwide rights to develop and commercialize NUPLAZID.
About Parkinson's Disease Psychosis
According to the National Parkinson Foundation, about one million people in the United States and from four to six million people worldwide suffer from Parkinson's disease. An estimated 40 percent of these patients have Parkinson's disease psychosis, which is characterized by hallucinations and delusions, is associated with significant caregiver burden, and is a major reason for nursing home placement among Parkinson's patients.
About California Life Sciences Association (CLSA)
California Life Sciences Association (CLSA) is the state's largest and most influential life sciences advocacy and business leadership organization. With offices in Sacramento, San Diego, South San Francisco, Los Angeles and Washington DC, CLSA works closely with industry, government, academia and others to shape public policy, improve access to innovative technologies and grow California's life sciences economy. CLSA serves biotechnology, pharmaceutical, medical device and diagnostics companies, research universities and institutes, investors and service providers throughout the Golden State. CLSA was founded in 2015 when the Bay Area Bioscience Association (BayBio) and the California Healthcare Institute (CHI) merged. Visit CLSA at www.califesciences.org, and follow us on Twitter @CALifeSciences, Facebook, Instagram, LinkedIn and YouTube.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders. ACADIA maintains a website at www.acadia-pharm.com to which we regularly post copies of our press releases as well as additional information and through which interested parties can subscribe to receive email alerts.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements include but are not limited to statements related to the progress and timing of ACADIA's drug discovery and development programs, and the benefits to be derived from NUPLAZID™ (pimavanserin), including the promise or significance of NUPLAZID and whether it will improve the lives of people with Parkinson's disease psychosis, and ACADIA's product candidates. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug discovery, development, approval and commercialization, and in collaborations with others, and the fact that past results of clinical trials may not be indicative of future trial results. For a discussion of these and other factors, please refer to ACADIA's annual report on Form 10-K for the year ended December 31, 2015 as well as ACADIA's subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and ACADIA undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.
Important Safety Information and Indication for NUPLAZID (pimavanserin) tablets
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. NUPLAZID is not approved for the treatment of patients with dementia-related psychosis unrelated to the hallucinations and delusions associated with Parkinson's disease psychosis.
NUPLAZID is an atypical antipsychotic indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.
QT Interval Prolongation: NUPLAZID prolongs the QT interval. The use of NUPLAZID should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong QT interval including Class 1A antiarrhythmics or Class 3 antiarrhythmics, certain antipsychotic medications, and certain antibiotics. NUPLAZID should also be avoided in patients with a history of cardiac arrhythmias, as well as other circumstances that may increase the risk of the occurrence of torsade de pointes and/or sudden death, including symptomatic bradycardia, hypokalemia or hypomagnesemia, and presence of congenital prolongation of the QT interval.
Adverse Reactions:Themost common adverse reactions(≥2% for NUPLAZID and greater than placebo) wereperipheral edema (7% vs 2%), nausea (7% vs 4%), confusional state (6% vs 3%), hallucination (5% vs 3%), constipation (4% vs 3%), and gait disturbance (2% vs <1%).
Drug Interactions:Strong CYP3A4 inhibitors (eg, ketoconazole) increase NUPLAZID concentrations. Reduce the NUPLAZID dose by one-half. Strong CYP3A4 inducers may reduce NUPLAZID exposure, monitor for reduced efficacy. Increase in NUPLAZID dosage may be needed.
Renal Impairment: No dosage adjustment for NUPLAZID is needed in patients with mild to moderate renal impairment. Use of NUPLAZID is not recommended in patients with severe renal impairment.
Hepatic Impairment: Use of NUPLAZID is not recommended in patients with hepatic impairment. NUPLAZID has not been evaluated in this patient population.
Pregnancy: Use of NUPLAZID in pregnant women has not been evaluated and should therefore be used in pregnancy only if the potential benefit justifies the potential risk to the mother and fetus.
Pediatric Use: Safety and efficacy have not been established in pediatric patients.
Dosage and Administration: Recommended dose: 34 mg per day, taken orally as two 17-mg tablets once daily, without titration.
For additional Important Safety Information, including boxed warning, please see the full Prescribing Information for NUPLAZID at http://www.acadia-pharm.com/wp-content/uploads/2016/04/NUPLAZID-pimavanserin-Package-Insert.pdf.
Read more: http://www.nasdaq.com/press-release/acadia-pharmaceuticals-receives-california-life-sciences-associations-2016-pantheon-dina-award-for-20161011-00363#ixzz4MmX6QcKu
____________________________________________
ACAD
Whew!! Incredibly close with 78707 shares traded @ $2.00.
ACAD
Surprised down so much because 3 directors should have been aware of the offering and bought at $2.56:
BAKER JULIAN Director 10/03/2016 Acquisition (Non Open Market) indirect 24,897 2.5600 7,174,124
GOWEN MAXINE Director 10/03/2016 Buy direct 4,102 2.5600 10,543
ZEIN YOUSSEF EL Director 10/03/2016 Buy direct 4,228 2.5600 516,892
Read more: http://www.nasdaq.com/symbol/idra/insider-trades#ixzz4MQZoIgU2
IDRA
Nov 11th data as posted by $heff:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=125561005
Bought @ $2.20 yesterday just before the drop and added @ $2.00 today. Thought the financing would be at higher level than $2.00. Gotta believe it will close soon.
IDRA
You should have written the SA Blog:
Quote
__________________________________________________________
Acadia Pharmaceuticals (NASDAQ:ACAD) has continue to drift down over the last week. Leerink Swann initiated the shares as a Market Perform with a $34 price target yesterday. However, the analyst did have some optimism in his notes ""We continue to believe that pimavanserin (NUPLAZID) is one of the most differentiated commercial stage assets in CNS and could be attractive to multiple potential buyers, including BIIB (MP) and AGN (OP). However, we are resuming coverage with a neutral view on the stock based on (1) our belief that the pimavanserin roll-out will be slow and steady, given the drug's high price tag and the intrinsic challenges associated with assisting high out-of-pocket cost for Medicare patients and (2) our caution surrounding the upcoming readout for pimavanserin in Alzheimer's Disease Psychosis {ADP}, for which we believe there exists at least some credit in the stock today."
Piper Jaffray is a bit more enthusiastic this morning as they reissue their Buy rating with a $44 price target. Its analyst notes that Nuplazid will probably have a slow rollout but should eventually garner near $1 billion in annual sales.
Acadia feels very much like Relypsa (NASDAQ:RLYP) did early this year. The company will have initial challenges moving from a development firm to a commercial one. The stock will also ebb & flow on every new buyout rumor or lack thereof. In the end, I think the company will share a similar fate with Relypsa that was bought out in July for a 60% premium although I don't see a deal until the first half of 2017 and the most logical suitor remains Biogen (NASDAQ:BIIB).
_____________________________________________
http://seekingalpha.com/article/4010277-biotech-forum-daily-digest-follow-progenics-dynavaxs-roller-coaster-week-spotlight-scynexis
ACAD
You are probably correct. Not sure I have the conviction to stay around. Today was a chance to accumulate more, but still down from them.
Hope BB begin to buy a few more. They have a >$5M hit on their most recent purchase alone:
"Advisors Lp Baker acquired 1,303,030 shares of the stock in a transaction dated Wednesday, August 10th. The shares were bought at an average cost of $33.00 per share, for a total transaction of $42,999,990.00. The disclosure for this purchase can be found here. Insiders own 21.65% of the company’s stock".
You long?
ACAD
Consensus Ratings for Acadia Pharmaceuticals (NASDAQ:ACAD)
Ratings Breakdown: 3 Hold Ratings, 7 Buy Ratings
Consensus Rating: Buy (Score: 2.70)
Consensus Price Target: $46.22 (50.51% upside)
______________________________________________-
https://www.marketbeat.com/stocks/NASDAQ/ACAD/
ACAD
Leerink Partners Starts Acadia Pharmaceuticals (ACAD) at Market Perform
October 4, 2016 6:43 AM EDT Tweet Share E-mail
Leerink Partners initiates coverage on Acadia Pharmaceuticals (NASDAQ: ACAD) with a Market Perform rating and a price target of $34.00.
Analyst Paul Matteis commented, "We continue to believe that pimavanserin (NUPLAZID) is one of the most differentiated commercial stage assets in CNS and could be attractive to multiple potential buyers, including BIIB (MP) and AGN (OP). However, we are resuming coverage with a neutral view on the stock based on (1) our belief that the pimavanserin roll-out will be slow and steady, given the drug's high price tag and the intrinsic challenges associated with assisting high out-of-pocket cost for Medicare patients and (2) our caution surrounding the upcoming readout for pimavanserin in Alzheimer's Disease Psychosis (ADP), for which we believe there exists at least some credit in the stock today."
Shares of Acadia Pharmaceuticals closed at $30.71 yesterday.
_______________________________________________________
http://www.streetinsider.com/Analyst+Comments/Leerink+Partners+Starts+Acadia+Pharmaceuticals+%28ACAD%29+at+Market+Perform/12097588.html
Thanks Leerink!!!
ACAD
Piper Jaffray Cos. Reiterates Overweight Rating for Acadia Pharmaceuticals Inc. (ACAD)
Posted by Nolan Pearson on Oct 3rd, 2016 // No Comments
Acadia Pharmaceuticals logoAcadia Pharmaceuticals Inc. (NASDAQ:ACAD)‘s stock had its “overweight” rating reaffirmed by research analysts at Piper Jaffray Cos. in a note issued to investors on Monday. They presently have a $44.00 target price on the biopharmaceutical company’s stock. Piper Jaffray Cos.’s price target would suggest a potential upside of 38.32% from the stock’s current price.
Other equities research analysts also recently issued reports about the company. Vetr downgraded Acadia Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $45.04 target price for the company. in a report on Monday, June 6th. Jefferies Group reissued a “buy” rating on shares of Acadia Pharmaceuticals in a research note on Wednesday, August 10th. Needham & Company LLC reissued a “buy” rating and issued a $49.00 price objective on shares of Acadia Pharmaceuticals in a research note on Tuesday, July 26th. HC Wainwright reissued a “buy” rating and issued a $60.00 price objective on shares of Acadia Pharmaceuticals in a research note on Monday, August 8th. Finally, JMP Securities reissued a “buy” rating and issued a $45.00 price objective on shares of Acadia Pharmaceuticals in a research note on Wednesday, August 10th. Four investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. Acadia Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $45.80.
Analyst Recommendations for Acadia Pharmaceuticals (NASDAQ:ACAD)
Acadia Pharmaceuticals (NASDAQ:ACAD) traded down 3.46% during trading on Monday, reaching $30.71. The company’s stock had a trading volume of 1,770,109 shares. The firm’s market capitalization is $3.50 billion. Acadia Pharmaceuticals has a 52-week low of $16.64 and a 52-week high of $43.30. The stock’s 50-day moving average is $33.17 and its 200 day moving average is $32.69.
Acadia Pharmaceuticals (NASDAQ:ACAD) last announced its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.49) by $0.14. Acadia Pharmaceuticals had a negative net margin of 131,066.23% and a negative return on equity of 64.25%. The company had revenue of $0.97 million for the quarter, compared to analysts’ expectations of $0.71 million. During the same period in the prior year, the company earned ($0.39) earnings per share. The company’s revenue for the quarter was up 96900.0% on a year-over-year basis. On average, analysts predict that Acadia Pharmaceuticals will post ($2.15) EPS for the current fiscal year.
In related news, Director Edmund Harrigan acquired 1,000 shares of the stock in a transaction dated Tuesday, August 16th. The shares were acquired at an average price of $32.97 per share, with a total value of $32,970.00. Following the acquisition, the director now owns 1,000 shares in the company, valued at approximately $32,970. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Bros. Advisors Lp Baker acquired 1,303,030 shares of the stock in a transaction dated Wednesday, August 10th. The shares were bought at an average cost of $33.00 per share, for a total transaction of $42,999,990.00. The disclosure for this purchase can be found here. Insiders own 21.65% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Tower Research Capital LLC TRC raised its position in shares of Acadia Pharmaceuticals by 1,529.8% in the second quarter. Tower Research Capital LLC TRC now owns 4,205 shares of the biopharmaceutical company’s stock worth $136,000 after buying an additional 3,947 shares in the last quarter. Winslow Evans & Crocker Inc. raised its position in shares of Acadia Pharmaceuticals by 120.0% in the second quarter. Winslow Evans & Crocker Inc. now owns 4,400 shares of the biopharmaceutical company’s stock worth $143,000 after buying an additional 2,400 shares in the last quarter. BlackRock Inc. raised its position in shares of Acadia Pharmaceuticals by 139.5% in the first quarter. BlackRock Inc. now owns 5,414 shares of the biopharmaceutical company’s stock worth $152,000 after buying an additional 3,153 shares in the last quarter. IFP Advisors Inc raised its position in shares of Acadia Pharmaceuticals by 28.7% in the first quarter. IFP Advisors Inc now owns 5,468 shares of the biopharmaceutical company’s stock worth $153,000 after buying an additional 1,219 shares in the last quarter. Finally, Pacad Investment Ltd. bought a new position in shares of Acadia Pharmaceuticals during the second quarter worth approximately $198,000. 92.10% of the stock is currently owned by institutional investors and hedge funds.
Acadia Pharmaceuticals Company Profile
ACADIA Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system disorders. The Company’s lead drug candidate, NUPLAZID (pimavanserin), is under development for the treatment of Parkinson’s disease psychosis (PDP).
______________________________________________
http://www.wkrb13.com/markets/1751270/piper-jaffray-cos-reiterates-overweight-rating-for-acadia-pharmaceuticals-inc-acad.html
ACAD
3 Top Biotech Stocks to Buy in October
October 02, 2016, 03:05:00 PM EDT By Brian Feroldi, Sean Williams, and Todd Campbell, Motley Fool
The biotech industry is on pace for a down year: The First Trust NYSE Arca Biotech ETF (NYSEMKT: FBT) , an exchange-traded fund that holds a broad portfolio of biotech stocks, has descended by double digits since the start of 2016, badly lagging the S&P 500 .
That hints at the possibility that there might be bargains to be found in the sector, so we asked some Motley Fool healthcare contributors to highlight stocks they think are great buys right now. Here's what they had to say.
Moving into massive markets
Todd Campbell : Acadia Pharmaceuticals (NASDAQ: ACAD) recently launched its first and only commercial drug, Nuplazid, and the company's third-quarter earnings will give investors their first detailed look at whether or not it's winning traction among doctors as a treatment for hallucinations and delusions in Parkinson's disease patients.
Parkinson's disease psychosis, or PDP, affects about 40% of the 1 million patients with Parkinson's disease, and until now doctors had no other option than to prescribe antipsychotics off-label that can interfere with other Parkinson's medications. Because Nuplazid controls PDP symptoms without that drawback, it could be a top-seller.
If Q3 results show Nuplazid sales are ramping up quickly, then Acadia's stock could enjoy tailwinds in Q4, but an even bigger market-moving event may be the company's upcoming release of data from a trial evaluating Nuplazid in Alzheimer's disease psychosis.
If those results, which are expected prior to year's end, show that Nuplazid works for those with Alzheimer's disease, then they could clear the way for Nuplazid's use by another population of more than 1 million people. At least 25% of the 5 million Americans with Alzheimer's disease suffer from hallucinations and delusions.
Admittedly, there's no guarantee that doctors will flock to Nuplazid, nor that Acadia Pharmaceuticals' Alzheimer's disease trial will pan out. Nevertheless, the potential upside makes me think this is a stock worth buying in October.
Read more: http://www.fool.com/investing/2016/10/02/3-top-biotech-stocks-to-buy-in-october.aspx#ixzz4M3030T4K
ACAD
Back in ACAD today @ $30.80. It has had a rough couple of weeks but now over-sold:
BB are top holder:
BAKER BROS. ADVISORS LP 06/30/2016 24,516,738 302,900 1.25 779,877
Read more: http://www.nasdaq.com/symbol/acad/institutional-holdings#ixzz4M1yk5VW6
ACAD
With close to 100% institutional ownership got to believe (and hope) that a few were selling low to get ZOES off their books at this quarter end. Otherwise hard to fathom the last two days.
Institutional Ownership 107.20%
Total Shares Outstanding (millions) 19
Total Value of Holdings (millions) $469
Read more: http://www.nasdaq.com/symbol/zoes/institutional-holdings#ixzz4LlzIj0C7
New quarter Monday.
ZOEES
Out TUBE $9.23. It has hit $9.24 but a lot of shares at that price, unless the MMs have a fake wall. Look to re-enter -- lot of room overhead.
TUBE
Back in TUBE @ $8.90.
Two nice long-term news releases today:
09/21/2016 9:00AM GlobeNewswire Inc. TubeMogul Augments Display Offering Through Expanded Partnerships, Enhanced Algorithms NASDAQ:TUBE Tubemogul, Inc. (MM)
09/21/2016 9:00AM GlobeNewswire Inc. TubeMogul Adds Native Advertising NASDAQ:TUBE Tubemogul, Inc. (MM)
TUBE
Out of TUBE today @ $9.23 to break even (had bought a few dip shares). Look to re-enter. So much potential, but every day seems to hit high before noon and drifts down the rest of the day.
TUBE
WARRANTS gone:
_______________________________________________
Aeterna Zentaris Announces Expiration of Remaining Series B Warrants
Today : Wednesday 14 September 2016
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the “Company”) today announced that the remaining 8,064 Series B Common Share Purchase Warrants (the “Series B Warrants”) issued in connection with the Company’s March 2015 financing expired on September 12, 2016 without being exercised. The Company had 9,939,863 Common Shares issued and outstanding as of the close of business on September 13, 2016.
David A. Dodd, President and Chief Executive Officer of the Company, explained, “All Series B Warrants issued in connection with our March 2015 financing have now been extinguished. Therefore, there will be no further dilution of our shareholders as a result of the Series B Warrants. I am pleased that we can report that the repair of our capital structure is now complete. We are looking forward to the impending completion of the pivotal, Phase III trials for Macrilen™ and Zoptrex™ and to the submission of NDAs for the products, if the results of the trials warrant doing so.”
About Aeterna Zentaris Inc.
Aeterna Zentaris is a specialty biopharmaceutical company engaged in developing and commercializing novel treatments in oncology, endocrinology and women’s health. We are engaged in drug development activities and in the promotion of products for others. We are now conducting Phase 3 studies of two internally developed compounds: Macrilen™ and Zoptrex™. The focus of our business development efforts is the acquisition of licenses to products that are relevant to our therapeutic areas of focus. We also intend to license out certain commercial rights of internally developed products to licensees in territories where such out-licensing would enable us to ensure development, registration and launch of our product candidates. Our goal is to become a growth-oriented specialty biopharmaceutical company by pursuing successful development and commercialization of our product portfolio, achieving successful commercial presence and growth, while consistently delivering value to our shareholders, employees and the medical providers and patients who will benefit from our products. For more information, visit www.aezsinc.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160914005365/en/
Aeterna Zentaris Inc.
Philip A. Theodore, 843-900-3223
Senior Vice President
ir@aezsinc.com
___________________________________________
AEZS
Thanks, fOMO is strong. Easier to do when looking for a short gain. Look to re-enter ACAD and hope to be in whenever the rumored buy-out comes, but supposedly that will be the 4th quarter.
From Fool yesterday:
Quote:
_________________________________________________________
One biotech that could be up for grabs
Todd Campbell: Few companies have successfully developed therapies that target Parkinson's disease, but Acadia Pharmaceuticals (NASDAQ:ACAD) is one of them. With evidence that Nuplazid reduced hallucinations and delusions in Parkinson's disease patients during clinical trials, the FDA approved the drug in April.
That approval makes Nuplazid the only FDA-approved therapy for Parkinson's disease psychosis, and investors will soon discover whether or not that monopoly position translates into a blockbuster commercial success. Acadia Pharmaceuticals officially launched Nuplazid on May 31, so third-quarter results should provide some color on how quickly doctors are embracing it. Since about 40% of the 4 million people suffering from Parkinson's disease suffer from psychosis, the potential exists for this drug to be a top seller.
If so, then Acadia Pharmaceuticals would benefit handsomely. Rather than sign on a partner during development, the company retained full global rights to Nuplazid. As a result, if Nuplazid gets off to a strong start, Acadia Pharmaceuticals could be in a prime position to negotiate global rights to the drug, or an outright sale of itself. Potential acquirers wouldn't be limited only to those working on Parkinson's disease, either. Nuplazid is in late-stage studies in Alzheimer's disease psychosis, too. Results from a phase 2 Alzheimer's disease trial are anticipated later this year, and if those results are solid, it could significantly expand Nuplazid's addressable patient population. Between 25% to 50% of the 5 million Americans suffering from Alzheimer's disease also suffer from Alzheimer's disease psychosis.
Admittedly, investors could already be pricing a premium for a potential merger or acquisition into shares. Despite lacking sales and spending $72 million on expenses last quarter, the company's market cap exceeds $3.2 billion. Nevertheless, Nuplazid's potential makes me think that Acadia Pharmaceuticals could fetch even more than that from an acquirer. Of course, that depends a lot on Nuplazid's sales ramp and the upcoming Alzheimer's disease data, so investors will want to stay tuned.
__________________________________
http://www.fool.com/investing/2016/09/11/3-stocks-begging-for-a-buyout.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2
ACAD
Sold @ $32.45, my target for day. Hope to re-enter, but took small profit on a good LABU day.
ACAD
Bought back in at $ $31.05 at the EOD on Friday. Suppose could have done better, but you never know.
MMs had it down to $30.14 earlier today which gave me pause. Seems they do this kinda thing a lot with ACAD.
ACAD
Glad you asked because I was thinking it was today @ noon. IT IS Monday the 12th at noon:
http://usda.mannlib.cornell.edu/MannUsda/viewDocumentInfo.do?documentID=1046
CORN
Waiting for the report on a low bid. It really moves the very second that the report is released. Gonna be a big candle day.
CORN
Likewise, I do it often -- too cheap to pay the price and unwilling to chase.
For me too close to buy before the Friday report unless it really dips tomorrow.
Have no idea what the heat in the Midwest is doing to the crop, if anything.
CORN